Transgene SA

First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent's BT-001 in Patients with Rectal Cancer

05 Nov 2026 02:00:00 By Nasdaq GlobeNewswire

Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery

03 Nov 2026 11:45:00 By Nasdaq GlobeNewswire

Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026

05 Oct 2026 02:00:00 By Nasdaq GlobeNewswire

Transgene to Participate in Investor Access

01 Oct 2026 11:45:00 By Nasdaq GlobeNewswire

2026 Half-Year Financial Report

24 Sep 2026 11:45:00 By Nasdaq GlobeNewswire

Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field

24 Sep 2026 11:45:00 By Nasdaq GlobeNewswire

Availability of Transgene’s Half-Year Financial Report as of June 30, 2026

24 Sep 2026 11:45:00 By Nasdaq GlobeNewswire

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line

08 Sep 2026 01:30:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025

12 Jan 2026 12:00:00 By Nasdaq GlobeNewswire

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

09 Jan 2026 02:00:00 By Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

17 Dec 2025 11:45:00 By Nasdaq GlobeNewswire

Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets

26 Nov 2025 18:15:00 By Nasdaq GlobeNewswire

Transgene Successfully Completes a Fundraising of c. €105 Million

26 Nov 2025 17:32:58 By Nasdaq GlobeNewswire

Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

25 Nov 2025 14:41:55 By Nasdaq GlobeNewswire

Correction: Transgene launches a fundraising campaign for approximately 105 million euros

25 Nov 2025 13:15:54 By Nasdaq GlobeNewswire

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

06 Nov 2025 02:30:00 By Nasdaq GlobeNewswire

Transgene Provides Business and Financial Update for Q3 2025

04 Nov 2025 11:50:00 By Nasdaq GlobeNewswire

New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse

04 Nov 2025 11:45:00 By Nasdaq GlobeNewswire

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

20 Oct 2025 02:30:00 By Nasdaq GlobeNewswire

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

13 Oct 2025 02:30:00 By Nasdaq GlobeNewswire